RNS Number : 4931R
Beximco Pharmaceuticals Ltd
30 April 2009
BEXIMCO PHARMACEUTICALS LTD.
30th April, 2009
PRICE SENSITIVE INFORMATION
Beximco Pharmaceuticals Limited ('BPL' or 'Company'; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors in their meeting held on 30th April, 2009 at 5.00 p.m. has decided the following:
|
1. Revaluation of Assets of the Company:
|
Accepted an independent report on the valuation of
Lands, Buildings, Plant and Machinery as of 31 December, 2008 issued by M/S S F Ahmed & Co. Chartered Accountants and Valuer showing an aggregate depreciated current cost of Tk 5,485,286,356 resulting in a revaluations surplus aggregating Tk 1,711,174,747
|
|
2. Date & Time of 33rd AGM of the:
Company for the year 2008
|
16th June, 2009 at 9.30 a.m
|
|
3. Proposed Dividend:
|
10% Cash and 20% Stock dividend
for the year ended 31 December 2008
|
|
4. Record date:
|
25th May, 2009.
|
|
5. Venue of AGM:
|
1 Shahbag C/A, Dhaka, Bangladesh
|
For further enquiries please contact:
Beximco Pharma
Nazmul Hassan, CEO
MD. ASAD ULLAH, FCS, Company Secretary
Tel: +880 2 861 9151, ext.2080
Libertas Capital
Jakob Kinde / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
Jonathan Birt / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFBLFXKZBEBBX